0.000USD0.000盘前交易 06/24, 09:30 (美东)
关键数据
24.985今开
25.235最高
82.01M成交量
18.77市盈率 TTM
8.75市盈率动
1.720股息TTM
1.44%换手率
25.080昨收
24.690最低
1.20B成交额
17.50市盈率静
1.63市净率
6.96%股息率 TTM
3.62%ROA
28.74552周最高
1.58量比
8.03B净利润
5.69B总股本
1.3167每股收益TTM
0.30Beta
8.29%ROE
23.06052周最低
2.17%振幅
68.24%毛利率
140.89B总市值
-2.36回报/风险
1.34%风险率
操作建议
辉瑞当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在药品行业排名80/157位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价29.03。中期看,股价处于下降通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
辉瑞简介
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
公司代码PFE
公司辉瑞
CEOBourla (Albert)
网址https://www.pfizer.com/
常见问题
根据分析师评级,辉瑞(PFE)的总体评级为signal_hold,目标价格为29.03。
辉瑞(PFE)股票的每股收益(EPS TTM)是多少
辉瑞(PFE)股票的每股收益(EPS TTM)是1.37。